BeiGene aims to be a next-generation oncology innovator by broadening its drug and pipeline portfolio to various solid tumors in addition to blood cancers. As such, it been actively investing to build ...

Indrayani Biotech Limited was incorporated in 1992. The Company came out with a public issue in 1994 to part-finance its project to produce cut flowers strawberries tissue culture plantlets and hybrid ...

From expanding an infectious disease assay portfolio to pioneering an imaging system to enhance space biology, here are the products, partnerships and publications that have been announced over the ...

The Board of Directors of Vardhman Special Steels Ltd in its meeting held today has recommended final dividend @ Rs.3/- per share. Shares of Vardhman Special Steels Limited was last trading in BSE ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Biotech Beach Hotbed includes San Diego, Los Angeles and the surrounding (Torrey Pines, Thousand Oaks) regions of Southern California. SoCal is well-known for its sprawling beaches and ...

Medicamen Biotech, operating in the Pharmaceuticals sector and classified as a Smallcap on the BSE, currently has its share price at ₹480.95. The stock has experienced fluctuations today ...

NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN). Such investors ...

Rossari Biotech Limited was founded in 2003 as a partnership firm in the name of Rossari Labtech by Mr. Edward Walter Menezes and Mr. Sunil Srinivasan Chari who are both career-technocrats ...

April 16, 2025--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird" or "the Company") today announced that after three weeks of engagement, including a timeline extension, Ayrmid Ltd ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...